FSA Advisors Inc. Makes New Investment in Merck & Co., Inc. $MRK

Key Points

• FSA Advisors acquired a new position in Merck (NYSE:MRK) of 11,280 shares valued at about $1.187 million in the fourth quarter, per its SEC filing.
• Merck beat Q1 expectations with revenue and adjusted EPS above Street forecasts and set FY2026 guidance of $5.04–$5.16 EPS, supported by growth in Keytruda and recent regulatory/pipeline wins.
• Company insiders sold roughly 320,176 shares (~$38.3M) last quarter, while analysts maintain a consensus “Moderate Buy” rating with a $128.18 target, indicating mixed sentiment.

FSA Advisors Inc. acquired a new position in Merck & Co., Inc. (NYSE:MRK - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,280 shares of the company's stock, valued at approximately $1,187,000.

Several other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Merck & Co., Inc. by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after acquiring an additional 2,185,853 shares in the last quarter. DLD Asset Management LP increased its position in shares of Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock valued at $3,986,675,000 after buying an additional 11,000,000 shares in the last quarter. Legal & General Group Plc increased its position in shares of Merck & Co., Inc. by 5.9% in the third quarter. Legal & General Group Plc now owns 20,659,157 shares of the company's stock valued at $1,733,923,000 after buying an additional 1,156,112 shares in the last quarter. Invesco Ltd. increased its position in shares of Merck & Co., Inc. by 16.6% in the third quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock valued at $1,665,585,000 after buying an additional 2,821,766 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Merck & Co., Inc. by 20.7% in the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock valued at $1,336,877,000 after buying an additional 2,735,459 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Up 0.1%

MRK opened at $112.30 on Monday. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The firm has a market cap of $277.36 billion, a P/E ratio of 31.63, a PEG ratio of 2.27 and a beta of 0.18. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $125.14. The business's fifty day simple moving average is $117.69 and its 200 day simple moving average is $107.70.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 26.84% and a net margin of 13.59%.The business's revenue for the quarter was up 4.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 4.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MRK. Wells Fargo & Company dropped their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an "overweight" rating for the company in a research report on Friday. Barclays began coverage on Merck & Co., Inc. in a research report on Friday, February 20th. They issued an "overweight" rating and a $140.00 price target for the company. Zacks Research upgraded Merck & Co., Inc. from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 17th. Guggenheim raised their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a "buy" rating in a research report on Friday, February 6th. Finally, Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 price target for the company in a research report on Friday, February 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $128.18.

Insider Buying and Selling at Merck & Co., Inc.

In related news, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the stock in a transaction on Friday, February 6th. The stock was sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the sale, the insider owned 21,197 shares of the company's stock, valued at $2,583,278.39. This trade represents a 41.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Chirfi Guindo sold 10,000 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer directly owned 70,615 shares in the company, valued at approximately $8,361,522.15. The trade was a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 320,176 shares of company stock valued at $38,281,735. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
• Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2‑drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long‑term growth optionality. Merck expands beyond oncology
• Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
• Neutral Sentiment: FY‑2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
• Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck‑specific news. Moderna Covid vaccine drives growth
• Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.